Generalized Pustular Psoriasis (GPP) - Competitive Landscape

Generalized Pustular Psoriasis (GPP) - Competitive Landscape


Summary

This reports provides a data-driven overview of the current and future competitive landscape in GPP therapeutics.
  • More than 21,700 diagnosed prevalent cases of GPP are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for GPP.
  • The majority of marketed drugs indicated to treat GPP are monoclonal antibodies.
  • Out of eight molecules in the pipeline for GPP, the late-stage pipeline includes only one drug in pre-registration and one drug in Phase III.
  • Commercial sponsors lead the clinical trials space for GPP over the past 10 years. AbbVie is the top sponsor in GPP clinical research with seven clinical trials, of which two are in Phase III.
  • In deals involving companies developing GPP assets, acquisitions was the most prevalent deal type in North America and merger was the most prevalent deal type in Asia-pacific.
Scope

GlobalData’s GPP: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the GPP market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GPP market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Key Findings
  • Disease Overview
    • Disease Etiology
  • Epidemiology Overview
    • Epidemiology Overview – Diagnosed Prevalent Cases of GPP in 2023 and 2028
  • Treatment Overview
    • Treatment Guidelines
  • Marketed Drugs Assessment
    • Marketed Drugs – Leading Marketed Drugs in GPP
    • Marketed Drugs – Overview by Mechanism of Action
    • Marketed Drugs – Overview by Route of Administration
    • Marketed Drugs – Overview by Molecule Type
    • Marketed Drug Profile – AbbVie's Skyrizi
    • Marketed Drug Profile – Novartis' Cosentyx
    • Marketed Drug Profile – UCB's Cimzia
    • Marketed Drug Profile – UCB's Bimzelx
    • Marketed Drug Profile – AstraZeneca's Lumicef
    • Marketed Drug Profile – Bristol-Myers Squibb's Sotyktu
    • Marketed Drug Profile – Boehringer Ingelheim's Spevigo
  • Pricing and Reimbursement Assessment
    • Marketed Drugs – Annual Cost of Therapy
    • Marketed Drugs – Time to Pricing and Reimbursement for Risankizumab
    • Marketed Drugs – Time to Pricing and Reimbursement for Secukinumab
    • Marketed Drugs – Time to Pricing and Reimbursement for Certolizumab Pegol
    • Marketed Drugs – Time to Pricing and Reimbursement for Bimekizumab
    • Marketed Drugs – Time to Pricing and Reimbursement for Brodalumab
    • Marketed Drugs – Time to Pricing and Reimbursement for Deucravacitinib
    • Marketed Drugs – Time to Pricing and Reimbursement for Spesolimab
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview – Late-Stage Pipeline Drugs in GPP
    • Pipeline Drugs – Overview by Development Stage
    • Pipeline Drugs – Overview by Mechanism of Action
    • Pipeline Drugs – PTSR and LoA in GPP
    • Pipeline Drugs – PTSR and LoA in Immunology and Psoriasis
  • Clinical Trials Assessment
    • Clinical Trials in GPP – Historical Overview
    • Clinical Trials in GPP – Overview by Phase
    • Clinical Trials in GPP – Overview by Status
    • Clinical Trials in GPP – Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in GPP – Trials with a Virtual Component
    • Clinical Trials in GPP – Geographic Overview
    • Clinical Trials in GPP – Single-Country and Multinational Trials by Region
    • Clinical Trials in GPP – Top Sponsors with Breakdown by Phase
    • Clinical Trials in GPP – Top Sponsors with Breakdown by Status
    • Clinical Trials in GPP – Overview by Endpoint Status
    • Clinical Trials in GPP – Overview by Race and Ethnicity
    • Clinical Trials in GPP – Enrollment Data
    • Clinical Trials in GPP – Overview of Sites by Geography
    • Clinical Trials in GPP – Top 20 Countries for Trial Sites
    • Clinical Trials in GPP – Top 20 Sites Globally
    • Clinical Trials – Feasibility Analysis: Geography Overview
    • Clinical Trials – Feasibility Analysis: Benchmark Models for GPP
  • Deals Landscape
    • Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in GPP by Region
  • Commercial Assessment
    • Commercial Assessment – Key Market Players in GPP
  • Future Market Catalysts
    • Future Market Catalysts – Upcoming Market Catalysts in GPP
  • Appendix
    • Methodology
    • Methodology – Sales Forecasts
    • Methodology – Pricing and Reimbursement
    • Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings